Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Research & Development (2016 - 2025)

Cardiff Oncology's Research & Development history spans 15 years, with the latest figure at $5.1 million for Q4 2025.

  • For Q4 2025, Research & Development fell 47.75% year-over-year to $5.1 million; the TTM value through Dec 2025 reached $35.3 million, down 4.14%, while the annual FY2025 figure was $35.3 million, 4.13% down from the prior year.
  • Research & Development for Q4 2025 was $5.1 million at Cardiff Oncology, down from $8.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $11.6 million in Q2 2025 and bottomed at $3.3 million in Q1 2021.
  • The 5-year median for Research & Development is $7.9 million (2023), against an average of $7.5 million.
  • The largest annual shift saw Research & Development surged 119.82% in 2022 before it tumbled 47.75% in 2025.
  • A 5-year view of Research & Development shows it stood at $5.8 million in 2021, then rose by 10.61% to $6.4 million in 2022, then increased by 20.51% to $7.8 million in 2023, then rose by 25.11% to $9.7 million in 2024, then crashed by 47.75% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Research & Development are $5.1 million (Q4 2025), $8.2 million (Q3 2025), and $11.6 million (Q2 2025).